Offering will provide robust, standardised tools for research and drug discovery.
23.05.2023Offering will provide robust, standardised tools for research and drug discovery.
Offering will provide robust, standardised tools for research and drug discovery.
23.05.2023Offering will provide robust, standardised tools for research and drug discovery.
Weslie Janeway - investor, philanthropist, and scientist - joins bit.bio's Board of Directors.
11.05.2023This collaboration will combine the Mekonos novel ex vivo delivery platform with bit.bio’s opti-ox precision cellular reprogrammin...
04.05.2023Statement from our CFO on the situation concerning SVB.
12.03.2023bit.bio will use Automata to automate a key aspect of its production of iPSC derived human cells
26.01.2023New advisors will provide important and independent guidance.
25.10.2022The award was presented at evening ceremony in central London.
17.06.2022The posters demonstrate the capability of opti-ox technology to create any human cell.
15.06.2022bit.bio wins biotech of the year for the second time and CEO of the year for Mark Kotter.
11.05.2022